Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD

Reichardt, Wilfried; Romaker, Daniel; Becker, Anne E.; Buechert, Martin; Walz, Gerd; Elverfeldt, Dominik von

doi:10.1007/s10334-008-0158-7

Cited by 22 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies demonstrated that kidney volume can be quantified in an unbiased fashion with minimum intra- and inter-observer variabilities. However, because of the use of CM, most of these studies did not include patients with CKD [3,9,11,16]. Moreover, gadolinium even seems to modify the TRV measurement in ADPKD patients.…”

Section: Discussionmentioning

confidence: 99%

“…In previous studies, [2,3,7,8,9,10,11,12,14,15,16] several authors described methods for TRV assessment in ADPKD patients based on the analysis of data acquired using iodinated CM or gadolinium. These studies demonstrated that kidney volume can be quantified in an unbiased fashion with minimum intra- and inter-observer variabilities.…”

Section: Discussionmentioning

confidence: 99%

“…However, it involves ionizing radiation and iodinated CM, which cannot be administered to patients with impaired renal function. MRI with gadolinium has been used as well and provides excellent tissue contrast and no need for ionizing radiation or iodinated CM [10,11,12]. However, gadolinium has also important limitations leading to the development of nephrogenic systemic fibrosis in CKD patients [13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Kidney Volume in Polycystic Kidney Disease Using Magnetic Resonance Imaging without Contrast Medium

Mignani¹,

Corsi

Marco

et al. 2011

Am J Nephrol

View full text Add to dashboard Cite

Background/Aims: Total renal volume (TRV) is an important index to evaluate the progression of autosomal-dominant polycystic kidney disease (ADPKD). TRV has been assessed by manually tracing renal contours from CT or MR scans, often employing contrast medium (CM). We developed a fast and nearly automated technique based on the analysis of MR images acquired without CM injection for TRV quantification. Methods: 30 ADPKD patients underwent MRI. After the selection of one point inside each kidney for the entire volume, the automatic extraction of kidney contours was performed on each acquired slice; the segmentation procedure was based on region growing and on the application of morphological operators and curvature-based motion. The area inside each contour was calculated and TRV was derived. Volume measurements were validated by comparison with measurements obtained by stereology. Results: TRV estimated in patients was 768 ± 545 ml (range 161–3,111 ml). The automatic measurements were in excellent correlation with the manual ones (r = 0.99, y = x – 0.7), with a small bias and narrow limits of agreement in both absolute (–5 ± 37 ml) and percentage (–0.6 ± 9.6%) terms. Conclusion: This preliminary study showed the feasibility of a fast and nearly automated method for determining TRV; importantly it does not require the use of potentially nephrotoxic CM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Kidney Volume in Polycystic Kidney Disease Using Magnetic Resonance Imaging without Contrast Medium

Mignani¹,

Corsi

Marco

et al. 2011

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…Recent studies have demonstrated the potential of using MRI to monitor the development of kidney cysts in animal models of cystic diseases (Reichardt et al, 2009). The surrounding parenchyma and cysts can be clearly distinguished by the differences in signal intensities between parenchyma Fig.…”

Section: Discussionmentioning

confidence: 99%

Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury

Aihara

Fujiki

Mizuguchi

et al. 2014

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Tolvaptan, a selective vasopressin V 2 receptor antagonist, slows the increase in total kidney volume and the decline in kidney function in patients with the results of the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Outcome (TEMPO) 3:4 trial. However, it was unclear which dose of tolvaptan was optimal or whether tolvaptan was able to delay progression to end-stage renal disease (ESRD). Here we examined the relationship with aquaresis and the inhibitory effect on cyst development in short-term treatment and mortality as an index of ESRD in long-term treatment with tolvaptan using DBA/2FG-pcy mice, an animal model of nephronophthisis. With short-term treatment from 5 to 15 weeks of age, tolvaptan (0.01-0.3% via diet) dose-dependently enhanced aquaresis, prevented increases in kidney weight and cyst volume, and was associated with significant reductions in kidney cAMP levels and extracellular signal-regulated kinase activity. Maximal effects of tolvaptan on aquaresis and the prevention of development of polycystic kidney disease (PKD) were obtained at 0.1%. Interestingly, tolvaptan also dose-dependently reduced urinary neutrophil gelatinase-associated lipocalin levels in correlation with the kidney volume. With long-term treatment from 5 to 29 weeks of age, tolvaptan significantly attenuated the increase in kidney volume by up to 50% and reduced urinary albumin excretion. Furthermore, tolvaptan significantly reduced the mortality rate to 20%, compared with 60% in the control group. These data indicate that tolvaptan may delay the onset of ESRD in PKD by suppressing the increases in kidney volume and renal injury, providing a promising treatment for PKD.

show abstract

“…The imaging of mouse kidneys has been performed in vivo primarily with X-ray micro-CT [2] and MRI [3,4,5]. Typically, the analysis of the images has been performed with extensive manual annotation [4,5].…”

Section: Introductionmentioning

confidence: 99%

Analysis of MR Images of Mice in Preclinical Treatment Monitoring of Polycystic Kidney Disease

Hadjidemetriou

Reichardt

Buechert³

et al. 2009

Medical Image Computing and Computer-Assisted Intervention – MICCAI 2009

Self Cite

View full text Add to dashboard Cite

Abstract.A common cause of kidney failure is autosomal dominant polycystic kidney disease (ADPKD). It is characterized by the growth of cysts in the kidneys and hence the growth of the entire kidneys with eventual failure in most cases by age 50. No preventive treatment for this condition is available. Preclinical drug treatment studies use an in vivo mouse model of the condition. The analysis of mice imaging data for such studies typically requires extensive manual interaction, which is subjective and not reproducible. In this work both untreated and treated mice have been imaged with a high field, 9.4T , MRI animal scanner and a reliable algorithm for the automated segmentation of the mouse kidneys has been developed. The algorithm first detects the region of interest (ROI) in the image surrounding the kidneys. A parameterized geometric shape for a kidney is registered to the ROI of each kidney. The registered shapes are incorporated as priors to the graph cuts algorithm used to extract the kidneys. The accuracy of the automated segmentation has been demonstrated by comparing it with a manual segmentation. The processing results are also consistent with the literature for previous techniques.

show abstract

Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD

Abstract: Using MRI, we were able to monitor the cystic volume in a mouse model of PKD to assess the therapeutic effect of anticystic treatment.

Cited by 22 publications

References 23 publications

Assessment of Kidney Volume in Polycystic Kidney Disease Using Magnetic Resonance Imaging without Contrast Medium

Assessment of Kidney Volume in Polycystic Kidney Disease Using Magnetic Resonance Imaging without Contrast Medium

Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury

Analysis of MR Images of Mice in Preclinical Treatment Monitoring of Polycystic Kidney Disease

Contact Info

Product

Resources

About